Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
47 (est)-2%
Dicerna Pharmaceuticals was founded in 2007 and is headquartered in Cambridge, US

Key People at Dicerna Pharmaceuticals

Douglas Fambrough

Douglas Fambrough

CEO
Bob D. Brown

Bob D. Brown

CSO

Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
87 Cambridge Park Dr

Dicerna Pharmaceuticals Data and Metrics

Dicerna Pharmaceuticals Financial Metrics

Dicerna Pharmaceuticals's revenue was reported to be $133 k in Q1, 2017
USD

Revenue (Q1, 2017)

133 k

Net income (Q1, 2017)

(14.2 m)

EBIT (Q1, 2017)

(14.2 m)

Market capitalization (22-Sep-2017)

94.9 m

Cash (31-Mar-2017)

22.9 m
Dicerna Pharmaceuticals's current market capitalization is $94.9 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

184 k295 k

Revenue growth, %

60%

R&D expense

29.5 m44 m41.7 m

General and administrative expense

15.6 m19.2 m18.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

184 k184 k184 k162 k133 k

R&D expense

6.8 m7.5 m8.7 m11.9 m12.1 m11.3 m11 m10.1 m8.9 m

General and administrative expense

4.4 m3.7 m5.4 m4.5 m4.9 m4.5 m4.7 m4.3 m5.5 m

Operating expense total

11.2 m11.2 m14.1 m16.4 m17 m15.7 m15.7 m14.4 m14.4 m
USDFY, 2014FY, 2015FY, 2016

Cash

26.1 m56.1 m20.9 m

Accounts Receivable

254.7 m805.4 k

Inventories

1.2 m1.5 m2 m

Current Assets

97.3 m96.1 m47.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

77.7 m31.8 m22.6 m25.9 m52.9 m27.6 m29.2 m32.5 m22.9 m

Current Assets

101.3 m93.7 m89.1 m96.7 m95.7 m81.8 m70.7 m59.4 m36.2 m

PP&E

1.5 m1.9 m2.3 m2.6 m2.7 m2.5 m2.5 m2.4 m2 m

Total Assets

124.2 m116 m92.7 m127.7 m113.6 m85.5 m74.3 m62.9 m39.4 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(47.9 m)(62.8 m)(59.5 m)

Depreciation and Amortization

848 k727 k840 k

Accounts Receivable

(15.1 m)

Inventories

(44.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(11.4 m)(11.2 m)(14.1 m)(16.2 m)(16.9 m)(15.7 m)(15.6 m)(14.2 m)(14.2 m)

Depreciation and Amortization

164 k

Accounts Payable

1.1 m1.2 m525 k1.6 m1.4 m2.4 m3.2 m3.7 m4.1 m

Cash From Operating Activities

(10.6 m)
USDY, 2017

Revenue/Employee

2.8 k

Financial Leverage

1.4 x
Show all financial metrics

Dicerna Pharmaceuticals Market Value History

Traffic Overview of Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Online and Social Media Presence

Dicerna Pharmaceuticals News and Updates

BRIEF-Dicerna appoints Martin Freed to board of directors

* Appointment will be effective immediately, and increases size of dicerna's board of directors to eight members Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Dicerna Pharmaceuticals Company Life and Culture

You may also be interested in